Loading
PDBj
メニューPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

5V4E

Engineered human IgG Fc domain glyco801 (Fc801)

5V4E の概要
エントリーDOI10.2210/pdb5v4e/pdb
分子名称Ig gamma-1 chain C region, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-2)-alpha-D-mannopyranose-(1-3)-[2-acetamido-2-deoxy-beta-D-glucopyranose-(1-2)-alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-[alpha-L-fucopyranose-(1-6)]2-acetamido-2-deoxy-beta-D-glucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-2)-alpha-D-mannopyranose-(1-3)-beta-D-mannopyranose, ... (10 entities in total)
機能のキーワードantibody engineering, fc fragment, igg, immune system
由来する生物種Homo sapiens (Human)
細胞内の位置Secreted : P01857
タンパク質・核酸の鎖数8
化学式量合計211247.08
構造登録者
Yan, W.,Marshall, N.,Zhang, Y.J. (登録日: 2017-03-09, 公開日: 2017-06-21, 最終更新日: 2024-11-20)
主引用文献Lee, C.H.,Romain, G.,Yan, W.,Watanabe, M.,Charab, W.,Todorova, B.,Lee, J.,Triplett, K.,Donkor, M.,Lungu, O.I.,Lux, A.,Marshall, N.,Lindorfer, M.A.,Goff, O.R.,Balbino, B.,Kang, T.H.,Tanno, H.,Delidakis, G.,Alford, C.,Taylor, R.P.,Nimmerjahn, F.,Varadarajan, N.,Bruhns, P.,Zhang, Y.J.,Georgiou, G.
IgG Fc domains that bind C1q but not effector Fc gamma receptors delineate the importance of complement-mediated effector functions.
Nat. Immunol., 18:889-898, 2017
Cited by
PubMed Abstract: Engineered crystallizable fragment (Fc) regions of antibody domains, which assume a unique and unprecedented asymmetric structure within the homodimeric Fc polypeptide, enable completely selective binding to the complement component C1q and activation of complement via the classical pathway without any concomitant engagement of the Fcγ receptor (FcγR). We used the engineered Fc domains to demonstrate in vitro and in mouse models that for therapeutic antibodies, complement-dependent cell-mediated cytotoxicity (CDCC) and complement-dependent cell-mediated phagocytosis (CDCP) by immunological effector molecules mediated the clearance of target cells with kinetics and efficacy comparable to those of the FcγR-dependent effector functions that are much better studied, while they circumvented certain adverse reactions associated with FcγR engagement. Collectively, our data highlight the importance of CDCC and CDCP in monoclonal-antibody function and provide an experimental approach for delineating the effect of complement-dependent effector-cell engagement in various therapeutic settings.
PubMed: 28604720
DOI: 10.1038/ni.3770
主引用文献が同じPDBエントリー
実験手法
X-RAY DIFFRACTION (3.216 Å)
構造検証レポート
Validation report summary of 5v4e
検証レポート(詳細版)ダウンロードをダウンロード

238895

件を2025-07-16に公開中

PDB statisticsPDBj update infoContact PDBjnumon